Table 2.
Variations of laboratory outcomes in relation to CoQ10 supplementation.
Variations of different laboratory outcomes after coenzyme Q10 supplementation along with IFN-β1a, compared with IFN-β1a alone. Laboratory measures repeated within each individual at baseline and after 3 and 6 months were included in mixed-effect linear regression models where we set an interaction term between time and treatment period (post-CoQ10 supplementation visit was at 3 months in Group 1, and at 6 months in Group 2). Coefficients (Coeff), 95% CI and p values are reported (p < 0.05 is presented as *).
| Primary endpoints | Coeff | 95% CI |
p values | |
|---|---|---|---|---|
| Lower | Upper | |||
| Markers of scavenging activity | ||||
| Uric acid, mg/dl | 0.123 | 0.009 | 0.237 | 0.034* |
| Bilirubin, mg/dl | 0.066 | −0.042 | 0.174 | 0.232 |
| Markers of oxidative damage | ||||
| CellROX cells, % | −9.925 | 018.353 | −1.497 | 0.021* |
| CellROX cells, MFI | −523.308 | −758.793 | −287.822 | <0.001* |
| Protein carbonyls, nmol/mg | −0.266 | −1.320 | 0.787 | 0.620 |
| 8-OHdG, ng/ml | −0.630 | −1.294 | −0.034 | 0.049* |
| Markers of inflammation | ||||
| EGF, pg/ml | −3.637 | −17.291 | 10.016 | 0.602 |
| Eotaxin, pg/ml | −18.669 | −36.643 | −0.695 | 0.042* |
| Basic-FGF, pg/ml | −2.736 | −24.007 | 18.535 | 0.801 |
| G-CSF, pg/ml | −4.692 | −16.508 | 7.124 | 0.436 |
| GM-CSF, pg/ml | −1.751 | −2.959 | −0.455 | 0.006* |
| HGF, pg/ml | −26.397 | −56.213 | −13.418 | 0.015* |
| IFN-α, pg/ml | 1.780 | −22.515 | 26.077 | 0.886 |
| IFN-γ, pg/ml | −1.526 | −2.878 | −0.175 | 0.027* |
| IL-1α, pg/ml | −2.460 | −5.313 | −0.591 | 0.040* |
| IL-1β, pg/ml | −1.188 | −3.531 | 1.153 | 0.320 |
| IL-1RA, pg/ml | −10.464 | −38.999 | 18.070 | 0.472 |
| IL-2, pg/ml | 5.099 | −11.619 | 21.817 | 0.550 |
| IL-2R, pg/ml | −29.971 | −54.330 | −5.612 | 0.016* |
| IL-3, pg/ml | 28.661 | −68.832 | 126.155 | 0.564 |
| IL-4, pg/ml | 3.883 | 0.843 | 6.923 | 0.012* |
| IL-5, pg/ml | −12.890 | −34.403 | 8.621 | 0.240 |
| IL-6, pg/ml | 5.559 | −46.568 | 57.687 | 0.834 |
| IL-7, pg/ml | −16.428 | −42.050 | 9.193 | 0.209 |
| IL-8, pg/ml | −11.418 | −23.830 | 0.993 | 0.071 |
| IL-9, pg/ml | −3.749 | −8.057 | −1.557 | 0.023* |
| IL-10, pg/ml | 1615.546 | −1399.093 | 4630.185 | 0.294 |
| IL-12, pg/ml | 2.498 | −11.569 | 16.566 | 0.728 |
| IL-13, pg/ml | 3.732 | 1.045 | 6.419 | 0.006* |
| IL-15, pg/ml | 21.693 | −37.211 | 80.597 | 0.470 |
| IL-17A, pg/ml | −0.453 | −1.508 | 0.602 | 0.400 |
| IL-17F, pg/ml | −68.854 | −140.017 | −12.307 | 0.034* |
| IL-22, pg/ml | −8.406 | −68.069 | 51.255 | 0.782 |
| IP-10, pg/ml | 5.699 | −44.344 | 55.743 | 0.823 |
| MCP-1, pg/ml | 39.540 | −45.290 | 124.371 | 0.361 |
| MIG, pg/ml | −5.409 | −19.197 | 8.379 | 0.442 |
| MIP-1α, pg/ml | −5.327 | −10.515 | −0.138 | 0.044* |
| MIP-1β, pg/ml | 17.125 | −49.443 | 83.695 | 0.614 |
| RANTES, pg/ml | −2331.281 | −3772.510 | 890.052 | 0.002* |
| TNF-α, pg/ml | −1.795 | −3.595 | −0.468 | 0.024* |
| VEGF, pg/ml | −0.398 | −0.821 | −0.052 | 0.042* |
CI, confidence interval; CoQ10, coenzyme Q10; IFN-β1a, interferon-beta1a 44μg; 8-hydroxy-2-deoxyguanosine (8-OHdG), epidermal growth factor (EGF), eotaxin, basic-fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), hepatocyte growth factor (HGF), interferon (IFN)-α, IFN-γ, interleukin (IL)-1α, IL-1β, IL-1RA, IL-2, IL-2R, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17A, IL-17F, IL-22, IFN-γ-inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-1, monokine induced by IFN-γ (MIG), macrophage inflammatory proteins (MIP)-1α, MIP-1β, regulated on activation-normal T cell expressed and secreted (RANTES), tumor necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF).